You are here

Approvals, Launches, and New Indications

In study, progression-free survival was superior to Rituxan-based therapy
This is the first new medicine for this population in two decades
First agency-approved treatment for pediatric and adult patients with MPS VII
FDA clears NSS-2 Bridge in an effort to reduce symptoms
New indication marks first adjuvant treatment after nephrectomy
First respiratory biologic with an eight-week maintenance dosing schedule
NK1 receptor antagonist helps with moderately and highly emetogenic chemotherapies
Medication previously approved for acute treatments
First new hepatitis B vaccine in 25 years requires only two doses
New approval covers the most common subtypes of cutaneous T-cell lymphoma
Merck drug associated with lower mortality through week 48 post-transplant
Positive phase 3 results comparing alectinib with crizotinib supported approval
Treatment for rare blood disease targets patients with BRAF V600 mutation
Topical monotherapy lowers pressure in the eye
Calquence demonstrated favorable overall response rate in initial studies
Phase 3 study demonstrated 10-mg dose reduced risk of recurrent VTE by up to 74%
Medication helps prevent nausea and vomiting after chemotherapy
Shingrix targets painful problem that strikes one in three
AstraZeneca introduces improved autoinjector

Pages